The past few years have seen massive growth in wellness and self-care and cannabinoid products growing immensely in popularity. It is definitely a ‘hot’ market space and one that has attracted headlines. Working with the Cellular team to become the first pure-play biosynthetic cannabinoid consumer products company to list on the London Stock Exchange was exactly the sort of pioneering challenge we relish.
It involved developing a clear narrative for the FCA along with in-depth analysis substantiating the legal use of cannabinoids and Cellular Goods’ application of them. Given that it was the first company in the space to list with the London Stock Exchange, this was a complex and lengthy process but one we made as fast and as a lean as possible. So, for instance, we constantly streamlined documents to ensure they were easy for the management team, none of whom were lawyers, to work through. Part of our enterprising and agile approach.
On 26 February 2021 Cellular Goods celebrated its successful listing raising £13m through a many times oversubscribed placing. Cellular Goods is now racing towards its product launch in September 2021.
It has been fantastic working with the team. You don't always find such agility combined with gravitas in the legal world.
